<!doctype html><html lang=en dir=auto>
<head><meta charset=utf-8>
<meta http-equiv=x-ua-compatible content="IE=edge">
<meta name=viewport content="width=device-width,initial-scale=1,shrink-to-fit=no">
<meta name=robots content="index, follow">
<title>Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients - Sarepta Therapeutics | Newsround</title>
<meta name=keywords content="business">
<meta name=description content="A t a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52) ELEVIDYS gene therapy demonstrated 70% or greater reduction in the rate of decline relative…">
<meta name=author content="None">
<link rel=canonical href=https://newsround.github.io/posts/sarepta-announces-positive-topline-three-year/>
<link rel=stylesheet href=/assets/css/common/main.css>
<link rel=stylesheet href=/assets/css/includes.css>
<link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css>
<link rel=stylesheet href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&family=Playfair+Display:wght@700&display=swap">
<link rel=stylesheet href=/assets/css/includes/cookieconsent.css>
<script src=/assets/js/cookieconsent.js></script>
<script type=module src=/assets/js/cookieconsent-config.js></script>
<link rel=icon href=https://newsround.github.io/favicon.ico>
<link rel=apple-touch-icon href=https://newsround.github.io/apple-touch-icon.png>
<meta name=theme-color content="#111828">
<meta name=msapplication-TileColor content="#111828">
<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-4988552421895566" crossorigin=anonymous></script>
<script async src="https://www.googletagmanager.com/gtag/js?id=G-1S4WSB17MB"></script>
<script>var doNotTrack=!1;if(!doNotTrack){window.dataLayer=window.dataLayer||[];function gtag(){dataLayer.push(arguments)}gtag('js',new Date),gtag('config','G-1S4WSB17MB',{anonymize_ip:!1})}</script>
<script type=text/javascript>gtag('consent','default',{ad_storage:'denied',ad_user_data:'denied',ad_personalization:'denied',analytics_storage:'denied'})</script><meta property="og:title" content="Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients - Sarepta Therapeutics">
<meta property="og:description" content="A t a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52) ELEVIDYS gene therapy demonstrated 70% or greater reduction in the rate of decline relative…">
<meta property="og:type" content="article">
<meta property="og:url" content="https://newsround.github.io/posts/sarepta-announces-positive-topline-three-year/"><meta property="og:image" content="https://newsround.github.io/posts/sarepta-announces-positive-topline-three-year/https:/investorrelations.sarepta.com/static-files/d0b28561-f14e-4a81-8ebf-739357b1b541"><meta property="article:section" content="posts">
<meta property="article:published_time" content="2026-01-26T13:00:00+00:00">
<meta property="article:modified_time" content="2026-01-26T13:00:00+00:00">
<meta name=twitter:card content="summary_large_image">
<meta name=twitter:image content="https://newsround.github.io/posts/sarepta-announces-positive-topline-three-year/https:/investorrelations.sarepta.com/static-files/d0b28561-f14e-4a81-8ebf-739357b1b541">
<meta name=twitter:title content="Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients - Sarepta Therapeutics">
<meta name=twitter:description content="A t a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52) ELEVIDYS gene therapy demonstrated 70% or greater reduction in the rate of decline relative…">
<script type=application/ld+json>{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":2,"name":"Posts","item":"https://newsround.github.io/posts/"},{"@type":"ListItem","position":3,"name":"Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients - Sarepta Therapeutics","item":"https://newsround.github.io/posts/sarepta-announces-positive-topline-three-year/"}]}</script>
<script type=application/ld+json>{"@context":"https://schema.org","@type":"BlogPosting","headline":"Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients - Sarepta Therapeutics","name":"Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients - Sarepta Therapeutics","description":"A t a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52) ELEVIDYS gene therapy demonstrated 70% or greater reduction in the rate of decline relative…","keywords":["business"],"articleBody":"A t a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52) ELEVIDYS gene therapy demonstrated 70% or greater reduction in the rate of decline relative…\n","wordCount":"40","inLanguage":"en","image":"https://newsround.github.io/posts/sarepta-announces-positive-topline-three-year/https:/investorrelations.sarepta.com/static-files/d0b28561-f14e-4a81-8ebf-739357b1b541","datePublished":"2026-01-26T13:00:00Z","dateModified":"2026-01-26T13:00:00Z","author":{"@type":"Person","name":"None"},"mainEntityOfPage":{"@type":"WebPage","@id":"https://newsround.github.io/posts/sarepta-announces-positive-topline-three-year/"},"publisher":{"@type":"Organization","name":"Newsround","logo":{"@type":"ImageObject","url":"https://newsround.github.io/favicon.ico"}}}</script>
</head>
<body class=min-h-screen id=top><nav class=navbar>
<div class=nav-container>
<a href=https://newsround.github.io/ title=Newsround>
<div class=logo>
<i class="fas fa-globe-americas"></i>
<h1>Newsround</h1>
</div>
</a>
<div class=nav-menu>
<a class=nav-link href=https://newsround.github.io/>Home</a>
<a class=nav-link href=https://newsround.github.io/tags/>Tags</a>
<a class=nav-link href=https://weather-pro.github.io/>Weather</a>
<a class=nav-link href=https://newsround.github.io/policy/>Privacy Policy</a>
</div>
<div class=nav-actions>
<div class=search-box>
<a title=Search href=https://newsround.github.io/search>
<button id=search-btn><i class="fas fa-search"></i></button>
</a>
</div>
<button class=theme-toggle id=theme-toggle>
<i class="fas fa-moon"></i>
</button>
</div>
<button class=mobile-menu-btn>
<i class="fas fa-bars"></i>
</button>
</div>
</nav>
<script type=text/javascript>const themeToggle=document.getElementById("theme-toggle");document.addEventListener("DOMContentLoaded",function(){loadTheme(),themeToggle.addEventListener("click",function(){toggleTheme()})});function loadTheme(){const a=localStorage.getItem("theme")||"light";a==="dark"&&(document.body.classList.add("dark-mode"),themeToggle.innerHTML='<i class="fas fa-sun"></i>')}function toggleTheme(){document.body.classList.toggle("dark-mode"),document.body.classList.contains("dark-mode")?(localStorage.setItem("theme","dark"),themeToggle.innerHTML='<i class="fas fa-sun"></i>'):(localStorage.setItem("theme","light"),themeToggle.innerHTML='<i class="fas fa-moon"></i>')}</script>
<main class=detail-content>
<div class=detail-container>
<button class=back-button onclick=goBack()>
<i class="fas fa-arrow-left"></i>
Back to News
</button>
<div class=detail-card>
<img alt="Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients - Sarepta Therapeutics" loading=lazy class=detail-image src=https://investorrelations.sarepta.com/static-files/d0b28561-f14e-4a81-8ebf-739357b1b541 onerror="this.onerror=null,this.src='/images/not-found-image.svg'">
<div class=detail-header style=display:block id=detail-header>
<div class=detail-meta>
<span class=detail-category>business</span>
<span class=detail-date>2026/01/26 13:00:00</span>
</div>
<h1 class=detail-title>Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients - Sarepta Therapeutics</h1>
<div class=detail-source>
<i class="fas fa-newspaper"></i>
<span>Source:Sarepta.com</span>
</div>
<div class=detail-author>Author:None</div>
</div>
<div class=detail-body style=display:block>
<div id=detail-content-text class=detail-content-text><p>A t a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52) ELEVIDYS gene therapy demonstrated 70% or greater reduction in the rate of decline relative…</p>
</div>
</div>
<div class=share-section style=display:block>
<h3 class=share-title>Share this article</h3>
<div class=share-buttons>
<a target=_blank rel="noopener noreferrer" aria-label="share Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients - Sarepta Therapeutics on facebook" href="https://facebook.com/sharer/sharer.php?u=https%3a%2f%2fnewsround.github.io%2fposts%2fsarepta-announces-positive-topline-three-year%2f" title="Facebook Share">
<button class="share-button facebook">
<i class="fab fa-facebook-f"></i>
Facebook
</button>
</a>
<a target=_blank rel="noopener noreferrer" aria-label="share Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients - Sarepta Therapeutics on twitter" href="https://twitter.com/intent/tweet/?text=Sarepta%20Announces%20Positive%20Topline%20Three-Year%20EMBARK%20Results%20Showing%20ELEVIDYS%20Significantly%20Slows%20Disease%20Progression%20on%20Key%20Functional%20Measures%20in%20Ambulatory%20Duchenne%20Patients%20-%20Sarepta%20Therapeutics&url=https%3a%2f%2fnewsround.github.io%2fposts%2fsarepta-announces-positive-topline-three-year%2f&hashtags=business" title="Twitter(X) Share">
<button class="share-button twitter">
<i class="fab fa-twitter"></i>
Twitter(X)
</button>
</a>
</div>
</div>
</div>
<div class=original-source style=display:block id=original-source>
<a href=https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-positive-topline-three-year-embark-results class=original-link target=_blank rel="noopener noreferrer">
<i class="fas fa-external-link-alt"></i>
Read full article on original source
</a>
</div>
<div class=related-articles>
<h2 class=section-title>
<i class="fas fa-newspaper"></i>
Related Articles
</h2>
<div class=related-grid>
<a href=https://newsround.github.io/posts/gold-and-silver-prices-fall-after-fridays-los/ aria-label="Gold and silver prices fall after Friday's losses - BBC">
<div class=news-card>
<img alt="Gold and silver prices fall after Friday's losses - BBC" class=news-image loading=lazy src=https://ichef.bbci.co.uk/news/1024/branded_news/b2ba/live/861bb460-ffed-11f0-8cad-0f51194f4bf1.jpg onerror="this.onerror=null,this.src='/images/not-found-image.svg'">
<div class=news-content>
<div class=news-meta>
<span class=news-category>business</span>
<span>2026/02/02 12:28:29</span>
</div>
<h3 class=news-title>Gold and silver prices fall after Friday's losses - BBC</h3>
<p class=news-description>Precious metal prices hit record highs in January as investors parked their money in &ldquo;safe …</p>
<div class=news-meta>
<span>BBC News</span>
<div class=read-more>
Read More <i class="fas fa-arrow-right"></i>
</div>
</div>
</div>
</div>
</a>
<a href=https://newsround.github.io/posts/illinois-indiana-among-6-states-included-in-d/ aria-label="Illinois, Indiana among 6 states included in distilled water recall - NBC 5 Chicago">
<div class=news-card>
<img alt="Illinois, Indiana among 6 states included in distilled water recall - NBC 5 Chicago" class=news-image loading=lazy src="https://media.nbcchicago.com/2023/03/GettyImages-1151133820-2.jpg?quality=85&strip=all&resize=1200%2C675" onerror="this.onerror=null,this.src='/images/not-found-image.svg'">
<div class=news-content>
<div class=news-meta>
<span class=news-category>business</span>
<span>2026/01/17 16:34:21</span>
</div>
<h3 class=news-title>Illinois, Indiana among 6 states included in distilled water recall - NBC 5 Chicago</h3>
<p class=news-description>Meijer, the Midwest-based grocery chain, is recalling more than 38,000 gallons of distilled water.</p>
<div class=news-meta>
<span>NBC Chicago</span>
<div class=read-more>
Read More <i class="fas fa-arrow-right"></i>
</div>
</div>
</div>
</div>
</a>
<a href=https://newsround.github.io/posts/the-fight-for-warner-bros-is-paramounts-most/ aria-label="The Fight for Warner Bros. Is Paramount’s Most Embarrassing Moment Yet - Gizmodo">
<div class=news-card>
<img alt="The Fight for Warner Bros. Is Paramount’s Most Embarrassing Moment Yet - Gizmodo" class=news-image loading=lazy src=https://gizmodo.com/app/uploads/2025/10/warner-bros-logo-1200x675.jpg onerror="this.onerror=null,this.src='/images/not-found-image.svg'">
<div class=news-content>
<div class=news-meta>
<span class=news-category>business</span>
<span>2026/01/19 23:00:49</span>
</div>
<h3 class=news-title>The Fight for Warner Bros. Is Paramount’s Most Embarrassing Moment Yet - Gizmodo</h3>
<p class=news-description>No one should be fighting for Warner Bros., but here we are, forced to pretend Paramount&rsquo;s …</p>
<div class=news-meta>
<span>Gizmodo.com</span>
<div class=read-more>
Read More <i class="fas fa-arrow-right"></i>
</div>
</div>
</div>
</div>
</a>
<a href=https://newsround.github.io/posts/jerome-powell-got-a-direct-question-about-the/ aria-label="Jerome Powell got a direct question about the U.S. ‘losing credibility’ and the soaring price of gold and silver. He punted - Fortune">
<div class=news-card>
<img alt="Jerome Powell got a direct question about the U.S. ‘losing credibility’ and the soaring price of gold and silver. He punted - Fortune" class=news-image loading=lazy src="https://fortune.com/img-assets/wp-content/uploads/2026/01/GettyImages-2258716137-e1769695337183.jpg?resize=1200,600" onerror="this.onerror=null,this.src='/images/not-found-image.svg'">
<div class=news-content>
<div class=news-meta>
<span class=news-category>business</span>
<span>2026/01/29 14:04:00</span>
</div>
<h3 class=news-title>Jerome Powell got a direct question about the U.S. ‘losing credibility’ and the soaring price of gold and silver. He punted - Fortune</h3>
<p class=news-description>Gold is up 84% year over year, and silver by a stunning 245%, but the Fed chair is looking …</p>
<div class=news-meta>
<span>Fortune</span>
<div class=read-more>
Read More <i class="fas fa-arrow-right"></i>
</div>
</div>
</div>
</div>
</a>
</div>
</div>
<div><script src=https://giscus.app/client.js data-repo=newsround/newsround.github.io data-repo-id=R_kgDOI7xTHw data-category=General data-category-id=DIC_kwDOI7xTH84C1EgU data-mapping=pathname data-strict=0 data-reactions-enabled=1 data-emit-metadata=0 data-input-position=bottom data-theme=preferred_color_scheme data-lang=en crossorigin=anonymous async></script>
</div>
</div>
</main>
<script type=text/javascript>function goBack(){document.referrer&&document.referrer.includes(window.location.hostname)?window.history.back():window.location.href="/"}</script>
<footer class=footer>
<div class=footer-content>
<div class=footer-section>
<div class=logo>
<i class="fas fa-globe-americas"></i>
<h3>Newsround</h3>
</div>
<p class=footer-description>
Newsround is a platform that provides the latest news and updates from around the world.
</p>
</div>
<div class=footer-section>
<h4>Quick Links</h4>
<ul class=footer-links>
<li>
<a href=https://newsround.github.io/>Home</a>
</li>
<li>
<a href=https://newsround.github.io/tags/>Tags</a>
</li>
<li>
<a href=https://weather-pro.github.io/>Weather</a>
</li>
<li>
<a href=https://newsround.github.io/policy/>Privacy Policy</a>
</li>
</ul>
</div>
<div class=footer-section>
<h4>News Categories</h4>
<ul class=footer-links>
<li>
<a href=/tags/general data-category=general>General News</a>
</li>
<li>
<a href=/tags/business data-category=business>Business & Finance</a>
</li>
<li>
<a href=/tags/technology data-category=technology>Technology</a>
</li>
<li><a href=/tags/sports data-category=sports>Sports</a></li>
<li>
<a href=/tags/health data-category=health>Health & Wellness</a>
</li>
</ul>
</div>
</div>
<div class=footer-bottom>
<p>
&copy; 2026 Newsround.All rights reserved.
</p>
<p>
Powered by <a href=https://newsapi.org/ target=_blank>NewsAPI</a>
</p>
</div>
</footer>
<a href=#top aria-label="go to top" title="Go to Top" id=top-link>
<button class=back-to-top id=back-to-top>
<i class="fas fa-chevron-up"></i>
</button>
</a>
<script type=text/javascript>document.querySelectorAll('a[href^="#"]').forEach(a=>{a.addEventListener("click",function(b){b.preventDefault();var a=this.getAttribute("href").substr(1);window.matchMedia('(prefers-reduced-motion: reduce)').matches?document.querySelector(`[id='${decodeURIComponent(a)}']`).scrollIntoView():document.querySelector(`[id='${decodeURIComponent(a)}']`).scrollIntoView({behavior:"smooth"}),a==="top"?history.replaceState(null,null," "):history.pushState(null,null,`#${a}`)})})</script>
<script>const gotop=document.querySelector("#top-link");window.onscroll=function(){document.body.scrollTop>400||document.documentElement.scrollTop>400?(gotop.style.visibility="visible",gotop.style.opacity="1"):(gotop.style.visibility="hidden",gotop.style.opacity="0")}</script></body>
</html>